PubMed Health⌕ Search

Biomedical subjects

G Kostner

Publications and source records attributed to G Kostner.

At least 19 recordsLinked to original sources

Silent mutations in secondary Shine-Dalgarno sequences in the cDNA of human serum amyloid A4 promotes expression of recombinant protein in Escherichia coli.

The serum amyloid A (SAA) superfamily comprises a number of differentially expressed genes with a high degree of homology in mammalian species. SAA4, an apolipoprotein constitutively expressed only in humans and mice, is associated almost entirely with lipoproteins of the high-density range. The presence of SAA4 mRNA and protein in macrophage-derived foam cells of coronary and carotid arteries suggested a specific role of human SAA4 during inflammation including atherosclerosis. Here we underline the importance of ribosome binding site (rbs)-like sequences (also known as Shine-Dalgarno sequences) in the SAA4 cDNA for expression of recombinant SAA4 protein in Escherichia coli. In contrast to rbs sequences coded by the expression vectors, rbs-like sequences in the cDNA of target protein(s) are known to interfere with protein translation via binding to the small 16S ribosome subunit, yielding low or even no expression. Here we show that PCR mutations of two rbs-like sequences in the human SAA4 cDNA promote expression of considerable amounts of recombinant SAA4 in E.coli.

Binding Sites↗

Lp(a) and the risk of coronary heart disease.

A screening study was performed on 106 children with familial risk for coronary heart disease (CHD) and on matched controls. The two groups differed in several parameters. Children of CHD patients exhibited significantly elevated levels of Lp(a) and total cholesterol, reduced HDL apo A1 and apo A2 and increased values of serum hexuronic acid. These results support the concept that genetic and familial factors contribute to the risk of atherosclerosis.

Adolescent↗

[Recent pathophysiologic aspects of atherogenesis].

Although the causes for atherogenesis are multifactorial, derangements of the lipid- and lipoprotein metabolism play a key role for the development of early lesions. The major risk factor for atherosclerosis cholesterol is a substance necessary for life. Cholesterol may be synthesized by any living cell of the human body. In order to save body fuel, cells take up cholesterol from circulation. All plasma lipids are bound in the blood to specific apolipoproteins. Apo-B containing lipoproteins are capable in binding to specific cell surface receptors (B/E-R) and to ingest cholesterol into the cells. Under circumstances, where the binding affinity to the B/E-R is reduced, atherogenic lipoproteins accumulate in the plasma and are eventually cleared by the scavenger receptor. These mechanisms play a key role in atherogenesis. Apo-A containing lipoproteins in contrast are designed to shuttle deposited cholesterol from the periphery to the liver, where it is oxidized to bile acids. The role of the four cell types:endothelial- and smooth muscle cells, macrophages and thrombocytes for atherogenesis in the concert with pathophysiological events of the lipid metabolism are discussed, and genetic diseases are explained at a molecular level.

Arteriosclerosis↗

[Modification of the atherogenic risk factor Lp(a) by supplementary fish oil administration in patients with moderate physical training].

Influence of supplementary fish oil diet in patients with moderate physical training on the atherogenic risk factor Lp(a) 32 male patients (mean age 54.0 +/- 5.8 years) were treated with supplementary fish oil intake (8 ml/d) and daily moderate swim training (20 to 30 min) for four weeks. In 22 of the 32 patients lipoprotein Lp(a) was reduced significantly by 25.0%, apolipoprotein (apo) B by 11.4%, apo A I by 7.8%, triglycerides by 38.3%, and cholesterol by 12.3%. Possibly caused by too low dosed fish oil no drop of Lp(a) was seen in ten patients. Caloric reduced diet (5000 kJ/d) did not effect additional decrease of the Lp(a) level. A control group of 22 male patients (52.9 +/- 5.7 control group of 22 male patients (52.9 +/- 5.7 years) trained in the same way received a supplementary peanut oil diet (8 ml/d). There was no influence on Lp(a) by n-6 PUFA but cholesterol and triglycerides dropped significantly.

Combined Modality Therapy↗

The Eberbach/Wiesloch Study: lipoprotein profiles of 35- to 49-year-old men and women.

Plasma lipid- and lipoprotein profiles of a representative sample of men and women aged 35 to 49 years in the Federal Republik of Germany were investigated. Mean plasma cholesterol levels, triglyceride levels, and phospholipid levels were significantly higher in men than in women. An extensive investigation of plasma lipoproteins, including measurement of all major apolipoproteins and lipids in each density class revealed profound sex differences in the distribution and composition of lipoproteins. In men mean plasma levels of VLDL-cholesterol (33.20 mg/dl) and of VLDL-triglycerides (155 mg/dl) were three times as high as in women (11.38 mg/dl and 50.08 mg/dl, respectively). The relative amount of triglyceride was 15% higher in VLDL of men, due to decreased relative amounts of VLDL-phospholipids. Intermediate-density lipoproteins (IDL) were significantly higher in men. Men had also higher levels of Apo B in low-density lipoproteins (LDL). Interestingly, LDL-cholesterol levels of men and women were not significantly different. Women had more high-density lipoproteins (HDL), and the absolute and relative amounts of HDL2-cholesterol were significantly higher in women. In summary, besides well-known sex differences in plasma lipid levels, sex-specific differences in the levels of certain plasma lipoproteins were observed. The most important finding was that the composition of the lipoproteins showed profound differences between men and women. With regard to risk for atherosclerotic cardiovascular disease, women have more favorable lipoprotein profiles than men. These data may provide a basis for further investigations on alterations in plasma lipid and lipoprotein profiles in respect to risk for atherosclerotic cardiovascular disease.

Adult↗

High-density lipoprotein composition is altered by a common DNA polymorphism adjacent to apoprotein AII gene in man.

25 of a group of 87 White men had Msp 1 restriction site polymorphism within an Alu sequence 3' to the human apo AII gene. Homozygosity for the polymorphism in 8 men was associated with a significant increase in serum apo AII levels (35.4 +/- 1.70 mg/dl, mean +/- SEM) and altered HDL composition, compared with heterozygotes (31.7 +/- 1.29; n = 17) and normal subjects (29.4 +/- 0.64; n = 62). This is the first account of a common variant of an HDL apoprotein gene that affects HDL composition. In view of its association with a high apo AII concentration homozygosity may protect against atherosclerosis.

Apolipoprotein A-I↗

Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.

Total and low density lipoprotein cholesterol concentration reduction in patients with markedly increased levels of these substances, leads to a decline in the incidence of myocardial infarction and death. A unique cholesterol-rich lipoprotein, lipoprotein Lp(a), has been identified which not only can be confused with low density lipoproteins, but has also been associated with premature cardiovascular disease. Using the cholesterol-lowering drugs neomycin and niacin in 14 type II hyperlipoproteinemic subjects, we determined the effect of lipid-lowering therapy on lipoprotein Lp(a) concentrations. Neomycin (2g/day) reduced low density lipoprotein cholesterol and lipoprotein Lp(a) concentrations by 23% and 24%, respectively. Combination therapy with neomycin (2 g/day) and niacin (3 g/day) induced a 48% decline in low density lipoprotein cholesterol levels and a 45% reduction in the concentration of lipoprotein Lp(a). These changes in lipoprotein Lp(a) levels were associated with a striking decline in the intensity of the slow pre-beta-lipoprotein fraction determined Lp(a) by lipoprotein electrophoresis. This slow pre-beta-lipoprotein fraction contained Lp(a) determined by immunofixation. These observations indicate that lipoprotein Lp(a) concentrations can be altered pharmacologically and that the progression of cardiovascular disease may be altered through changes in lipoprotein (a) levels.

Adult↗

Post-heparin lipolytic activity in acute renal failure.

Total post-heparin lipolytic activity (PHLA), hepatic triglyceride lipase (HTGL) and protamine inactivated lipoprotein lipase (LPL) and plasma lipoprotein pattern were investigated in 8 patients with acute renal failure (ARF). PHLA was determined at 5, 10, 15, 30, 45 and 60 minutes after heparin administration (100 U/kg b.w.). Maximal PHLA in ARF was 6.12 +/- 1.56 mumol FFA/ml/h at 10 minutes versus 14.62 +/- 4.29 at 45 min in controls (= 42%, p less than 0.001). PHLA was reduced in ARF throughout the study period (p less than 0.001). Maximal HTGL activity (3.06 +/- 0.84 mumol FFA/ml/h) was obtained at 10 min in ARF versus 8.97 +/- 3.11 after 15 min in controls (= 34%, p less than 0.001). HTGL in ARF differed from controls at all points of determination (p less than 0.001). LPL maximum was 3.12 +/- 1.93 mumol FFA/ml/h at 15 min in ARF and 7.65 +/- 3.44 at 45 min in controls (= 40%, p less than 0.001). LPL activity was different from controls at 30, 45 and 60 min (p less than 0.001) but not at 5, 10 and 15 min after heparin injection. Due to a rapid decrease of LPL activity (half maximal activity after 34 min in ARF versus 94 min in controls, p less than 0.05) activity half life of PHLA was diminished in ARF (49 min in ARF versus 112 min in controls, p less than 0.01). Thus both the activity of HTGL and LPL is impaired in ARF. Because of the different activation kinetics of the two PHLA fractions no conclusions concerning maximal enzyme activities can be drawn from single determinations as suggested in previous studies on chronic renal failure.

Acute Kidney Injury↗

Serum apolipoproteins and lipoprotein (a) during the first week of life.

The levels of apolipoproteins, A-I, A-II, B and E, lipoprotein (a) and of total cholesterol and triglycerides were determined in cord serum and in capillary serum at the fifth day of life in a group of 44 term newborns. Additionally, cord serum lipoproteins were estimated. Sera from 26 healthy adults were studied for comparison. The concentrations of lipids and lipoproteins in cord serum were diminished as compared to adult levels. The occurrence of lipoprotein (a) in cord serum in concentrations significantly lower than in adults could be established. Serum apolipoproteins A-I, A-II and B were significantly lower at birth than in the adult, whereas apolipoprotein E levels did not differ from adult concentrations. During the first five days apolipoprotein B levels more than doubled, apolipoprotein A-I increased moderately and apolipoprotein E rose slightly. In contrast, serum lipoprotein (a) and apolipoprotein A-II did not change significantly. Unlike serum cholesterol, the levels of apolipoproteins B and E at day five were significantly correlated to those measured at birth in the same infants. The changes of the apolipoprotein pattern during the first week of life reflect the evolution of the lipid transport system of the newborn and may be related to the increasing utilisation of fat and to hormonal factors.

Adult↗

Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia.

Nineteen hypercholesterolaemic patients were randomly treated with either 16 or 8 g cholestyramine with a changeover after 6 weeks for a second 6-week period. During a third consecutive 6-week period all patients received 4 g cholestyramine daily. The low density lipoprotein (LDL) cholesterol and triglyceride concentrations decreased significantly (- 11%, - 21% and - 26% for LDL cholesterol on 4, 8 and 16 g, respectively) with a dose-response effect. However, the increase from 8 g to 16 g only caused a modest additional reduction of the lipid levels. The serum concentration of apolipoprotein (apo) B was correlated to the LDL cholesterol and decreased similarly in a dose-response fashion. However, the average reduction of apo B was less pronounced (- 4%, - 13% and - 17% on 4, 8 and 16 g of cholestyramine, respectively) resulting in a significant change of the apo B/LDL cholesterol ratio during treatment. There was a significant increase of the high density lipoprotein (HDL) cholesterol concentration, which was similar at all dose levels. Also, the apo A-I concentration in serum increased significantly but the relative decrease was less pronounced than that of HDL cholesterol, causing a significant decrease of the apo A-I/HDL cholesterol ratio. The apo A-II concentration in serum was unchanged or slightly decreased and the apo A-I/apo A-II ratio increased significantly.

Adolescent↗

Studies on the possible function of beta 2-glycoprotein-I: influence in the triglyceride metabolism in the rat.

Seven rats were infused with 14C-labeled Intralipid at a constant rate of 0.38 ml per hour over a time period of 4 hours. Four rats served as controls and received an infusion of 0.15 M NaCl or of serum albumin two hours after the start of the experiment. In these animals the plasma triglyceride concentration rose linearly from 30 to 240 min and paralleled the total blood radioactivity. The triglyceride concentrations at the end of the experiments were about 25 times as high as at the beginning. Three rats receiving 2 hr after the start an additional infusion of beta 2-glycoprotein-I at a rate of 10 mg per hr showed a markedly enhanced triglyceride removal from the plasma, reaching a steady state which lasted for more than 30 min. It is concluded that beta 2-glycoprotein-I affects the triglyceride clearance under these experimental conditions.

Animals↗